Payment overview · 2025
General Payments
$1,402.73
63 reported records · 21 companies
Healthcare provider profile · identity verified
Jeffrey R Scheirer, DO
Allopathic & Osteopathic Physicians|Family Medicine · BERLIN, MD · NPI 1760593552
Verified facts
What the public records show
CMS Open Payments records show Jeffrey R Scheirer, DO received $1,402.73 in general payments during 2025 across 63 reported records.
Amgen Inc. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Jardiance, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $312.11 | 22.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $194.29 | 13.8% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $136.30 | 9.7% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $120.07 | 8.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.90 | 6.0% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $75.24 | 5.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.68 | 5.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.87 | 4.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.26 | 4.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.57 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.18 | 2.3% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.90 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.58 | 1.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $23.91 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.84 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.07 | 1.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.66 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.34 | 1.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.13 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.98 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.85 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,402.73 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $187.14 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $132.95 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $120.07 | 4 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $88.98 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $88.97 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $75.24 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.57 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.57 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.87 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $65.23 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.34 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.34 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.26 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.39 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.38 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.57 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.18 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 17 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 40 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
112 | 29 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
78 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 776 | 228 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 670 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 553 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 439 | 111 |
| Metformin Hcl | Metformin Hcl | 327 | 99 |
| Losartan Potassium | Losartan Potassium | 304 | 84 |
| Gabapentin | Gabapentin | 303 | 103 |
| Pravastatin Sodium | Pravastatin Sodium | 292 | 88 |
| Lisinopril | Lisinopril | 285 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 86 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 233 | 65 |
| Famotidine | Famotidine | 204 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 59 |
| Valsartan | Valsartan | 195 | 55 |
| Omeprazole | Omeprazole | 183 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 64 |
| Furosemide | Furosemide | 172 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 50 |
| Allopurinol | Allopurinol | 163 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 52 |
| Ezetimibe | Ezetimibe | 162 | 51 |
| Potassium Chloride | Potassium Chloride | 159 | 53 |
| Sertraline Hcl | Sertraline Hcl | 130 | 33 |
| Meloxicam | Meloxicam | 126 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 49 |
| Montelukast Sodium | Montelukast Sodium | 113 | 29 |
| Eliquis | Apixaban | 112 | 34 |
| Synthroid | Levothyroxine Sodium | 112 | 29 |
| Donepezil Hcl | Donepezil Hcl | 110 | 32 |
| Buspirone Hcl | Buspirone Hcl | 102 | 32 |
| Celecoxib | Celecoxib | 100 | 27 |
| Ibuprofen | Ibuprofen | 98 | 38 |
| Memantine Hcl | Memantine Hcl | 96 | 22 |
| Simvastatin | Simvastatin | 96 | 32 |
| Tramadol Hcl | Tramadol Hcl | 92 | 26 |
| Alprazolam | Alprazolam | 90 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 25 |
| Jardiance | Empagliflozin | 79 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 78 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 18 |
| Finasteride | Finasteride | 73 | 24 |
| Glipizide | Glipizide | 71 | 21 |
| Carvedilol | Carvedilol | 68 | 21 |
| Farxiga | Dapagliflozin Propanediol | 68 | 21 |
| Glipizide Er | Glipizide | 68 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 23 |
| Ramipril | Ramipril | 66 | 19 |
| Irbesartan | Irbesartan | 65 | 16 |
| Azithromycin | Azithromycin | 61 | 55 |
| Trazodone Hcl | Trazodone Hcl | 60 | 16 |
| Prednisone | Prednisone | 57 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 21 |
| Trulicity | Dulaglutide | 52 | 11 |
| Xarelto | Rivaroxaban | 52 | 16 |
| Alendronate Sodium | Alendronate Sodium | 51 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 16 |
| Clonazepam | Clonazepam | 48 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 18 |
| Naproxen | Naproxen | 47 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 23 |
| Lorazepam | Lorazepam | 45 | 21 |
| Valacyclovir | Valacyclovir Hcl | 44 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 12 |
| Spironolactone | Spironolactone | 43 | 14 |
| Amoxicillin | Amoxicillin | 42 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Lovastatin | Lovastatin | 41 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 40 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | 11 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 33 | 17 |
| Mirtazapine | Mirtazapine | 32 | 11 |
| Atenolol | Atenolol | 31 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Ibu | Ibuprofen | 30 | 11 |
| Nadolol | Nadolol | 29 | suppressed |
| Baclofen | Baclofen | 28 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Cefdinir | Cefdinir | 17 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | 11 |
| Fluconazole | Fluconazole | 16 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Estradiol | Estradiol | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,402.73 · 63 records | Amgen Inc. | ABRYSVO, AIRSUPRA, APTIMA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, EVENITY, FASENRA, GARDASIL 9, GEMTESA, INGREZZA, INJECTAFER, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, PYRUKYND, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VAXNEUVANCE, VOQUEZNA, VOWST, VRAYLAR, VYNDAQEL, Veozah, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error